[go: up one dir, main page]

AU8672198A - Method enabling readministration of aav vector via immunosuppression of host - Google Patents

Method enabling readministration of aav vector via immunosuppression of host

Info

Publication number
AU8672198A
AU8672198A AU86721/98A AU8672198A AU8672198A AU 8672198 A AU8672198 A AU 8672198A AU 86721/98 A AU86721/98 A AU 86721/98A AU 8672198 A AU8672198 A AU 8672198A AU 8672198 A AU8672198 A AU 8672198A
Authority
AU
Australia
Prior art keywords
readministration
host
aav vector
method enabling
vector via
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU86721/98A
Inventor
Varavani Dwarki
Jaime Escobedo
William C. Manning
John E. Murphy
Shang-Zhen Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU8672198A publication Critical patent/AU8672198A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU86721/98A 1997-07-31 1998-07-29 Method enabling readministration of aav vector via immunosuppression of host Abandoned AU8672198A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US5468997P 1997-07-31 1997-07-31
US5469297P 1997-07-31 1997-07-31
US5431897P 1997-07-31 1997-07-31
US5437297P 1997-07-31 1997-07-31
US60054372 1997-07-31
US60054692 1997-07-31
US60054318 1997-07-31
US60054689 1997-07-31
US5613997P 1997-08-19 1997-08-19
US60056139 1997-08-19
PCT/US1998/015794 WO1999006562A1 (en) 1997-07-31 1998-07-29 Method enabling readministration of aav vector via immunosuppression of host

Publications (1)

Publication Number Publication Date
AU8672198A true AU8672198A (en) 1999-02-22

Family

ID=27535252

Family Applications (1)

Application Number Title Priority Date Filing Date
AU86721/98A Abandoned AU8672198A (en) 1997-07-31 1998-07-29 Method enabling readministration of aav vector via immunosuppression of host

Country Status (5)

Country Link
EP (1) EP1002078A1 (en)
JP (1) JP2001512142A (en)
AU (1) AU8672198A (en)
CA (1) CA2297490A1 (en)
WO (1) WO1999006562A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221646B1 (en) 1997-07-31 2001-04-24 Chiron Corporation Materials and methods for simplified AAV production
US6464976B1 (en) 1999-09-07 2002-10-15 Canji, Inc. Methods and compositions for reducing immune response
JP2003511038A (en) * 1999-09-30 2003-03-25 カイロン コーポレイション Materials and methods for simplified AAV production
JP4960565B2 (en) 2000-05-12 2012-06-27 ジェンザイム コーポレーション Modulator of TNFα signaling
WO2001094605A2 (en) * 2000-06-09 2001-12-13 University Of Florida Research Foundation, Inc. Recombinant aav vectors for gene therapy of obesity
CA2423093C (en) 2000-09-25 2013-09-17 Valentis, Inc. Improved system for regulation of transgene expression
JP3785508B2 (en) * 2002-04-15 2006-06-14 学校法人慶應義塾 Experimental model mouse that can analyze immune response in gene therapy
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP2287323A1 (en) 2009-07-31 2011-02-23 Association Institut de Myologie Widespread gene delivery to the retina using systemic administration of AAV vectors
JP6385920B2 (en) 2012-05-09 2018-09-05 オレゴン ヘルス アンド サイエンス ユニバーシティー Adeno-associated virus plasmid and vector
US20150182637A1 (en) 2012-06-21 2015-07-02 Association Institut De Myologie Widespread gene delivery of gene therapy vectors
CA2912678C (en) * 2013-05-15 2023-10-10 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
IL305449B1 (en) 2016-04-15 2025-09-01 Univ Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
SG11202002457RA (en) 2017-09-22 2020-04-29 Univ Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
KR20200112811A (en) 2017-11-27 2020-10-05 코다 바이오테라퓨틱스 인코포레이티드 Composition and method for neurodegenerative diseases
EP3737768A1 (en) * 2018-01-11 2020-11-18 Chameleon Biosciences, Inc. Immuno-evasive vectors and use for gene therapy
EP3790979A4 (en) 2018-05-08 2022-04-27 Neuracle Science Co., Ltd Adeno-associated virus (aav) delivery of anti-fam19a5 antibodies
KR20210130158A (en) 2019-01-31 2021-10-29 오레곤 헬스 앤드 사이언스 유니버시티 Methods Using Transcription-Dependent Directed Evolution of AAV Capsids
US20220348635A1 (en) 2019-08-21 2022-11-03 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
WO2023212294A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Angiopoietin-related protein 7-specific antibodies and uses thereof
EP4514845A1 (en) 2022-04-29 2025-03-05 Broadwing Bio LLC Bispecific antibodies and methods of treating ocular disease
WO2023212293A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Complement factor h related 4-specific antibodies and uses thereof
WO2024227154A1 (en) 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof
WO2025184567A1 (en) * 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme

Also Published As

Publication number Publication date
WO1999006562A1 (en) 1999-02-11
EP1002078A1 (en) 2000-05-24
JP2001512142A (en) 2001-08-21
CA2297490A1 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
AU8672198A (en) Method enabling readministration of aav vector via immunosuppression of host
AU1584499A (en) Virtual wallet system
AU8140198A (en) Lipoproteins as nucleic acid vectors
ZA968170B (en) Method for transferring genes to the heart using aav vectors
AU6043598A (en) Method of displacement chromatography
AU6586598A (en) Method for simplying block matching motion estimation
AU3356197A (en) Method of isolating cyclosporins
AU7203496A (en) Novel peptides
AU6112498A (en) Method for assembly of multiple dna fragments
AU1458499A (en) Interface optimized computer system architecture
AU5644396A (en) Novel heterocyclic chemistry
AU6721696A (en) Cd44-like protein
AU3549397A (en) Over-expression of proteins
AU6489996A (en) Methods for increasing protein expression
AU2091799A (en) Uses of alpha-conotoxin peptides
AU3938697A (en) Novel lipolytic enzymes
AU5256998A (en) Electrophoresis system
EP0908939A3 (en) Method of mechanical polishing
AU2735897A (en) Ribosomes as vectors for rna
AU5284296A (en) Immune-evading proteins
AU6000698A (en) Proteins
AU7146698A (en) Method of determining three-dimensional protein structure from primary protein sequence
AU7423796A (en) Novel stress proteins
AU3036197A (en) Adenovirus vectors for gene therapy
AU8255498A (en) Methods of using electrically treated liquids

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase